KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) CEO Benjamin L. Palleiko sold 7,352 shares of the stock in a transaction on Monday, September 9th. The shares were sold at an average price of $12.19, for a total value of $89,620.88. Following the sale, the chief executive officer now directly owns 250,800 shares in the company, valued at approximately $3,057,252. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
KalVista Pharmaceuticals Price Performance
NASDAQ KALV opened at $11.21 on Wednesday. The company has a market cap of $484.50 million, a P/E ratio of -3.30 and a beta of 0.89. KalVista Pharmaceuticals, Inc. has a 12 month low of $7.21 and a 12 month high of $16.88. The company has a 50-day moving average of $13.16 and a 200-day moving average of $12.39.
KalVista Pharmaceuticals (NASDAQ:KALV – Get Free Report) last released its earnings results on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.91) by $0.04. As a group, equities research analysts anticipate that KalVista Pharmaceuticals, Inc. will post -3.57 EPS for the current year.
Institutional Trading of KalVista Pharmaceuticals
Analysts Set New Price Targets
A number of equities research analysts have recently commented on the stock. HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of KalVista Pharmaceuticals in a report on Friday, September 6th. Needham & Company LLC reaffirmed a “buy” rating and issued a $32.00 target price on shares of KalVista Pharmaceuticals in a research note on Friday, September 6th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of KalVista Pharmaceuticals in a research note on Monday.
Read Our Latest Research Report on KalVista Pharmaceuticals
KalVista Pharmaceuticals Company Profile
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.
See Also
- Five stocks we like better than KalVista Pharmaceuticals
- What is the Australian Securities Exchange (ASX)
- Matador Resources Insiders Keep Buying Its Stock, Should You?
- Upcoming IPO Stock Lockup Period, Explained
- Oracle Can Turn the Magnificent 7 Into 8: Here’s Why
- How to Calculate Return on Investment (ROI)
- Palantir Stock Is Up 14% on S&P 500 News: Is It Time to Buy?
Receive News & Ratings for KalVista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.